Migalastat Hydrochloride Purification for API-Grade Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing migalastat hydrochloride lack the capability to achieve high purity levels, particularly in intermediate and active pharmaceutical ingredient (API) grades, leading to impurities that can affect its efficacy in treating Fabry disease.
Innovation Solution
A multi-step process involving the synthesis and purification of 1,2,3,6-tetrapivaloyl-D-galactofuranoside and its derivatives, followed by reduction and hydrogenation steps, using high-performance liquid chromatography (HPLC) and hydrophilic interaction liquid chromatography (HILIC) to achieve purity levels of less than 3% for certain impurities and less than 0.5% for others, ensuring high-quality migalastat hydrochloride production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional production methods are used for migalastat hydrochloride, then the production process is simpler and more straightforward, but the purity of the final product is insufficient with impurity levels exceeding acceptable thresholds
Solution Approach 1:
The production process is divided into multiple discrete crystallization steps (first crystallization, second crystallization) and purification steps (HPLC, HILIC). Each step targets specific impurities and achieves incremental purity improvements, transforming a single complex purification challenge into manageable sequential operations.
Solution Approach 2:
The method performs preliminary purification actions during the crystallization steps before final HPLC/HILIC purification. By removing bulk impurities early through controlled crystallization conditions, the subsequent high-resolution chromatography steps can focus on trace impurities, improving overall efficiency and reducing solvent consumption.
2Manufacturing precision
If multiple purification steps including HPLC and HILIC are implemented, then the purity of migalastat hydrochloride exceeds 99.5%, but the production time and process complexity increase
Solution Approach 1:
The purification process uses periodic action through alternating HPLC and HILIC chromatography steps. Each chromatography mode targets different classes of impurities, and the periodic alternation between isocratic and gradient elution modes maximizes impurity removal efficiency while managing overall process time.
Solution Approach 2:
The method employs parameter changes by switching between different chromatography conditions (isocratic vs. gradient elution, different mobile phase compositions, different column types). These parameter variations optimize the separation of different impurity classes at each purification stage, achieving high purity through cumulative effect rather than relying on a single lengthy purification step.
3Manufacturing precision
If intermediate grade batches are purified using conventional methods, then the purification process is faster and less complex, but the final purity level remains below pharmaceutical grade requirements
Solution Approach 1:
The method uses intermediary purification steps (first crystallization, second crystallization) as mediators between the crude intermediate grade material and the final pharmaceutical grade product. These intermediary steps progressively transform the material quality, making each subsequent purification step more effective and easier to execute.
Solution Approach 2:
The method replaces simple mechanical filtration or decantation with advanced chromatographic techniques (HPLC, HILIC) that use chemical interactions (reversed-phase, hydrophilic interaction) for separation. This substitution enables the removal of trace impurities that cannot be eliminated by conventional mechanical means, achieving pharmaceutical grade purity.
4Manufacturing precision
If high-performance liquid chromatography and hydrophilic interaction liquid chromatography are used for purification, then impurity levels are reduced below 0.5%, but the cost of production and equipment complexity increase
Solution Approach 1:
The purification system uses multi-functional chromatographic equipment that can operate in different modes (HPLC with isocratic/gradient elution, HILIC with different mobile phases). This universal equipment performs multiple purification functions across different stages, reducing the need for separate specialized equipment and optimizing resource utilization.
Solution Approach 2:
The method employs composite purification strategies combining different chromatography modes (reversed-phase HPLC, hydrophilic interaction HILIC) with different crystallization approaches. This composite approach leverages the strengths of each technique for different impurity classes, achieving superior purification that would be impossible with any single method alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves migalastat hydrochloride with impurity levels below 0.5%, enhancing its therapeutic effectiveness and safety for treating Fabry disease, while maintaining cost-effectiveness and scalability.
Implementation Method 1
performing high performance liquid chromatography (HPLC) on the batch to identify a peak associated with the Compound B
Implementation Method 2
hydrophilic interaction liquid chromatography (HILIC) to achieve purity levels
Data Source
AI summary
Provided are methods of producing Active Pharmaceutical Ingredient (API) grade migalastat hydrochloride, and for purifying intermediate grade migalastat hydrochloride. Further provided are methods of producing [(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl) piperidine-3,4,5-triol hydrochloride (lucerastat hydrochloride) and other 1-deoxygalactonojirimycin compounds, as well as methods of purifying intermediate grade lucerastat hydrochloride and other 1-deoxygalactonojirimycin compounds.